Globally, the number of 3D printing patent applications for the pharmaceutical industry declined by 0.3% in Q3 2022 when compared to the preceding quarter. The total number of 3D printing-related grants dropped by 7% in Q3 2022, according to GlobalData’s Patent Analytics.
Notably, 336 3D-printing-related patent applications were filed in the pharmaceutical sector in Q3 2022 compared to 337 in prior quarter.
15% of patenting activity came from the top five largest companies
Arkema has filed the most patents related to 3D printing in the pharmaceutical industry operations sector and technologies sector during Q3 2022, according to an analysis of patenting activity. The quarter saw Arkema file 23 3D printing-related patents, up from 18 in the prior quarter. It was followed by Johnson & Johnson with 10 3D printing patent filings, Jabil (7 filings), and 3D Systems (6 filings) in Q3 2022.
The US was the main driver of patenting activity with 26% of total patent filings
With 26% of 3D printing patent filings, the US was the largest market for 3D printing patents in the pharmaceutical sector in Q3 2022. China (20%) and South Korea (10%) were close behind. The US represented 1% less of the 27% that it had in Q2 2022.